カテゴリー： QYResearch, 世界

発疹の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書（QY21APR2267）
◆英語タイトル：Global Exanthema Market Size, Status and Forecast 2021-2027
◆商品コード：QY21APR2267
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2021年4月
◆ページ数：91
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥499,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥748,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
本調査資料では、発疹の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、非抗生物質）、用途別市場規模（ルベオラ、風疹、伝染性紅斑、突発性発疹）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・発疹の市場動向
・企業の競争状況、市場シェア
・発疹の種類別市場規模（抗生物質、非抗生物質）
・発疹の用途別市場規模（ルベオラ、風疹、伝染性紅斑、突発性発疹）
・発疹の北米市場規模2016-2027（アメリカ、カナダ）
・発疹の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・発疹のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・発疹の中南米市場規模2016-2027（メキシコ、ブラジル）
・発疹の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Manus Aktteva Biopharma、Teva Pharmaceutical Industries、CIRON Drugs & Pharmaceuticals、Iol Chemicals and Pharmaceuticals、Mikart、Ranbaxy Laboratories、Hikma、Nexgen Pharma）
・結論
【レポートの概要】

An exanthem or exanthema is a widespread rash usually occurring in children. An exanthem can be caused by toxins, drugs, or microorganisms, or can result from autoimmune disease.
Geographically, North America dominated the exanthema market and Asia Pacific is projected to have fastest growth, owing to rapidly increasing awareness levels, modernizing healthcare infrastructure and favourable government support in this region.

Market Analysis and Insights: Global Exanthema Market
The global Exanthema market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Exanthema market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Exanthema market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Exanthema market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Exanthema market.

Global Exanthema Scope and Market Size
Exanthema market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Exanthema market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Antibiotic Drugs
Non-antibiotic Drugs

Segment by Application
Rubeola
Rubella
Erythema Infectiosum
Roseola Infantum

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Manus Aktteva Biopharma
Teva Pharmaceutical Industries
CIRON Drugs & Pharmaceuticals
Iol Chemicals and Pharmaceuticals
Mikart
Ranbaxy Laboratories
Hikma
Nexgen Pharma

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Exanthema Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antibiotic Drugs
1.2.3 Non-antibiotic Drugs
1.3 Market by Application
1.3.1 Global Exanthema Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Rubeola
1.3.3 Rubella
1.3.4 Erythema Infectiosum
1.3.5 Roseola Infantum
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Exanthema Market Perspective (2016-2027)
2.2 Exanthema Growth Trends by Regions
2.2.1 Exanthema Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Exanthema Historic Market Share by Regions (2016-2021)
2.2.3 Exanthema Forecasted Market Size by Regions (2022-2027)
2.3 Exanthema Industry Dynamic
2.3.1 Exanthema Market Trends
2.3.2 Exanthema Market Drivers
2.3.3 Exanthema Market Challenges
2.3.4 Exanthema Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Exanthema Players by Revenue
3.1.1 Global Top Exanthema Players by Revenue (2016-2021)
3.1.2 Global Exanthema Revenue Market Share by Players (2016-2021)
3.2 Global Exanthema Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Exanthema Revenue
3.4 Global Exanthema Market Concentration Ratio
3.4.1 Global Exanthema Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Exanthema Revenue in 2020
3.5 Exanthema Key Players Head office and Area Served
3.6 Key Players Exanthema Product Solution and Service
3.7 Date of Enter into Exanthema Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Exanthema Breakdown Data by Type
4.1 Global Exanthema Historic Market Size by Type (2016-2021)
4.2 Global Exanthema Forecasted Market Size by Type (2022-2027)

5 Exanthema Breakdown Data by Application
5.1 Global Exanthema Historic Market Size by Application (2016-2021)
5.2 Global Exanthema Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Exanthema Market Size (2016-2027)
6.2 North America Exanthema Market Size by Type
6.2.1 North America Exanthema Market Size by Type (2016-2021)
6.2.2 North America Exanthema Market Size by Type (2022-2027)
6.2.3 North America Exanthema Market Size by Type (2016-2027)
6.3 North America Exanthema Market Size by Application
6.3.1 North America Exanthema Market Size by Application (2016-2021)
6.3.2 North America Exanthema Market Size by Application (2022-2027)
6.3.3 North America Exanthema Market Size by Application (2016-2027)
6.4 North America Exanthema Market Size by Country
6.4.1 North America Exanthema Market Size by Country (2016-2021)
6.4.2 North America Exanthema Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Exanthema Market Size (2016-2027)
7.2 Europe Exanthema Market Size by Type
7.2.1 Europe Exanthema Market Size by Type (2016-2021)
7.2.2 Europe Exanthema Market Size by Type (2022-2027)
7.2.3 Europe Exanthema Market Size by Type (2016-2027)
7.3 Europe Exanthema Market Size by Application
7.3.1 Europe Exanthema Market Size by Application (2016-2021)
7.3.2 Europe Exanthema Market Size by Application (2022-2027)
7.3.3 Europe Exanthema Market Size by Application (2016-2027)
7.4 Europe Exanthema Market Size by Country
7.4.1 Europe Exanthema Market Size by Country (2016-2021)
7.4.2 Europe Exanthema Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Exanthema Market Size (2016-2027)
8.2 Asia-Pacific Exanthema Market Size by Type
8.2.1 Asia-Pacific Exanthema Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Exanthema Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Exanthema Market Size by Type (2016-2027)
8.3 Asia-Pacific Exanthema Market Size by Application
8.3.1 Asia-Pacific Exanthema Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Exanthema Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Exanthema Market Size by Application (2016-2027)
8.4 Asia-Pacific Exanthema Market Size by Region
8.4.1 Asia-Pacific Exanthema Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Exanthema Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Exanthema Market Size (2016-2027)
9.2 Latin America Exanthema Market Size by Type
9.2.1 Latin America Exanthema Market Size by Type (2016-2021)
9.2.2 Latin America Exanthema Market Size by Type (2022-2027)
9.2.3 Latin America Exanthema Market Size by Type (2016-2027)
9.3 Latin America Exanthema Market Size by Application
9.3.1 Latin America Exanthema Market Size by Application (2016-2021)
9.3.2 Latin America Exanthema Market Size by Application (2022-2027)
9.3.3 Latin America Exanthema Market Size by Application (2016-2027)
9.4 Latin America Exanthema Market Size by Country
9.4.1 Latin America Exanthema Market Size by Country (2016-2021)
9.4.2 Latin America Exanthema Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Exanthema Market Size (2016-2027)
10.2 Middle East & Africa Exanthema Market Size by Type
10.2.1 Middle East & Africa Exanthema Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Exanthema Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Exanthema Market Size by Type (2016-2027)
10.3 Middle East & Africa Exanthema Market Size by Application
10.3.1 Middle East & Africa Exanthema Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Exanthema Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Exanthema Market Size by Application (2016-2027)
10.4 Middle East & Africa Exanthema Market Size by Country
10.4.1 Middle East & Africa Exanthema Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Exanthema Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Manus Aktteva Biopharma
11.1.1 Manus Aktteva Biopharma Company Details
11.1.2 Manus Aktteva Biopharma Business Overview
11.1.3 Manus Aktteva Biopharma Exanthema Introduction
11.1.4 Manus Aktteva Biopharma Revenue in Exanthema Business (2016-2021)
11.1.5 Manus Aktteva Biopharma Recent Development
11.2 Teva Pharmaceutical Industries
11.2.1 Teva Pharmaceutical Industries Company Details
11.2.2 Teva Pharmaceutical Industries Business Overview
11.2.3 Teva Pharmaceutical Industries Exanthema Introduction
11.2.4 Teva Pharmaceutical Industries Revenue in Exanthema Business (2016-2021)
11.2.5 Teva Pharmaceutical Industries Recent Development
11.3 CIRON Drugs & Pharmaceuticals
11.3.1 CIRON Drugs & Pharmaceuticals Company Details
11.3.2 CIRON Drugs & Pharmaceuticals Business Overview
11.3.3 CIRON Drugs & Pharmaceuticals Exanthema Introduction
11.3.4 CIRON Drugs & Pharmaceuticals Revenue in Exanthema Business (2016-2021)
11.3.5 CIRON Drugs & Pharmaceuticals Recent Development
11.4 Iol Chemicals and Pharmaceuticals
11.4.1 Iol Chemicals and Pharmaceuticals Company Details
11.4.2 Iol Chemicals and Pharmaceuticals Business Overview
11.4.3 Iol Chemicals and Pharmaceuticals Exanthema Introduction
11.4.4 Iol Chemicals and Pharmaceuticals Revenue in Exanthema Business (2016-2021)
11.4.5 Iol Chemicals and Pharmaceuticals Recent Development
11.5 Mikart
11.5.1 Mikart Company Details
11.5.2 Mikart Business Overview
11.5.3 Mikart Exanthema Introduction
11.5.4 Mikart Revenue in Exanthema Business (2016-2021)
11.5.5 Mikart Recent Development
11.6 Ranbaxy Laboratories
11.6.1 Ranbaxy Laboratories Company Details
11.6.2 Ranbaxy Laboratories Business Overview
11.6.3 Ranbaxy Laboratories Exanthema Introduction
11.6.4 Ranbaxy Laboratories Revenue in Exanthema Business (2016-2021)
11.6.5 Ranbaxy Laboratories Recent Development
11.7 Hikma
11.7.1 Hikma Company Details
11.7.2 Hikma Business Overview
11.7.3 Hikma Exanthema Introduction
11.7.4 Hikma Revenue in Exanthema Business (2016-2021)
11.7.5 Hikma Recent Development
11.8 Nexgen Pharma
11.8.1 Nexgen Pharma Company Details
11.8.2 Nexgen Pharma Business Overview
11.8.3 Nexgen Pharma Exanthema Introduction
11.8.4 Nexgen Pharma Revenue in Exanthema Business (2016-2021)
11.8.5 Nexgen Pharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 発疹の世界市場規模・現状・予測2021年-2027年(Global Exanthema Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 後天性血友病A治療の世界市場規模・現状・予測2021年-2027年 ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. Market Analysis and Insights: Global Acquired hemophilia A Treatment Market The global Acquired hemophilia A Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acquired hemophilia A Treatment market to help players in achieving a strong market position....
  • 自動車におけるIIoTの世界市場規模・現状・予測2021年-2027年 Automotive industry has widely adopted virtual reality (VR) due to the prospect of cost and time reductions. Automotive applications such as manufacturing workstation optimization, vehicle design, and assembly training make use of VR. Automotive companies use VR for the virtual environment to determine the vehicle’s performance in various environments and car crashes. VR and IIoT collectively result in better designs for automobiles, speed-up the manufacturing processes, and help in delivering customer preferred standards. The integration of virtual reality in automotive industry is identified to be one of the key trends contributing towards the growth of the IIoT market in automotive...
  • 発疹の世界市場規模・現状・予測2021年-2027年 An exanthem or exanthema is a widespread rash usually occurring in children. An exanthem can be caused by toxins, drugs, or microorganisms, or can result from autoimmune disease. Geographically, North America dominated the exanthema market and Asia Pacific is projected to have fastest growth, owing to rapidly increasing awareness levels, modernizing healthcare infrastructure and favourable government support in this region. Market Analysis and Insights: Global Exanthema Market The global Exanthema market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and...
  • エキソストシン1/2ヘテロダイマーの世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Exostosin 1/2 Heterodimer Market The global Exostosin 1/2 Heterodimer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Exostosin 1/2 Heterodimer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Exostosin 1/2 Heterodimer market in terms...
  • 後天性血友病A治療の世界市場規模・現状・予測2021年-2027年 ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. Market Analysis and Insights: Global Acquired hemophilia A Treatment Market The global Acquired hemophilia A Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acquired hemophilia A Treatment market to help players in achieving a strong market position....
  • エキソストシン1/2ヘテロダイマーの世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Exostosin 1/2 Heterodimer Market The global Exostosin 1/2 Heterodimer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Exostosin 1/2 Heterodimer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Exostosin 1/2 Heterodimer market in terms...
  • スマートケーブルガードシステムの世界市場規模・現状・予測2021年-2027年 Smart cable guard system is capable of detecting partial discharges (PDs) or faults with a location accuracy of 1% of the cable length, and notifying the grid operator. Market Analysis and Insights: Global Smart Cable Guard System Market The global Smart Cable Guard System market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Smart Cable Guard System market to help players in...
  • 先端巨大症治療の世界市場規模・現状・予測2021年-2027年 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have closed. In this report, we study the drugs for Acromegaly. Market Analysis and Insights: Global Acromegaly Therapeutics Market The global Acromegaly Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acromegaly Therapeutics market to help players in achieving a strong market position. Buyers of the report can...
  • スウェーデンポルフィリン症治療薬の世界市場規模・現状・予測2021年-2027年 Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. Market Analysis and Insights: Global Swedish Porphyria Therapeutics Market The global Swedish Porphyria Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Swedish Porphyria Therapeutics market to help players in achieving a strong market position. Buyers of...
  • クロファラビンの世界市場規模・現状・予測2021年-2027年 Clofarabine is a purine nucleoside antimetabolite marketed in the US and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. Market Analysis and Insights: Global Clofarabine Market The global Clofarabine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Clofarabine market to help players in achieving a strong market position. Buyers of the report can...
  • スウェーデンポルフィリン症治療の世界市場規模・現状・予測2021年-2027年 Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. Market Analysis and Insights: Global Swedish Porphyria Treatment Market The global Swedish Porphyria Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Swedish Porphyria Treatment market to help players in achieving a strong market position. Buyers of...
  • サンドホフ病治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Sandhoff Disease Therapeutics Market The global Sandhoff Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Sandhoff Disease Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Sandhoff Disease Therapeutics market in terms...
  • インフィニバンド（InfiniBand）の世界市場規模・現状・予測2021年-2027年 InfiniBand specification is low-latency, high-bandwidth interconnect which has also usage in different input/output networks including storage area networks and cluster networks. Thousands of data centers, high-performance compute clusters and embedded applications are additionally propelling the market. The Global InfiniBand market includes Asia Pacific, North America, Asia and Middle East, Europe and Latin America. Particularly North America , is one of the fastest growing markets for InfiniBand, which the maximum growth rate followed by Asia Pacific and Europe. Market Analysis and Insights: Global InfiniBand Market The global InfiniBand market size is projected to reach US$ XX million by 2026, from US$...
  • 注射用ミカファンギンナトリウムの世界市場規模・現状・予測2021年-2027年 Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008. In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%. Market Analysis and...
  • イロプロスト薬の世界市場規模・現状・予測2021年-2027年 Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues. North America is estimated to have a major share in the global market with 75%. Market Analysis and Insights: Global Iloprost Drugs Market The global Iloprost Drugs market size is projected to reach US$ 83 million by 2026, from US$ 93 million in 2019, at a CAGR of -1.6% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key...